newsfilter
← Latest News
GlobeNewswire·

FibroGen Reports First Quarter 2025 Financial Results and Provides Business Update

Total consideration for the sale of FibroGen China to AstraZeneca now expected to be approximately $185 million, a $25 million increase from initial guidance Net cash held in China at closing now estimated to be